Annual Scientific Meeting

Breakfast D: Case-Based Functional GI Testing: Ask the Experts

Monday, October 8
6:30 AM - 7:45 AM
Location: 121A (level 100)

Category: Functional Bowel Disease

Admission to the optional breakfast sessions on Monday, Tuesday, and Wednesday may be purchased for $60 each; register online at until September 28, 2018. During the meeting, visit the Registration Desk to purchase admission; some sessions may be sold out.

Mark Pimentel

Director, GI Motility Program
Cedars-Sinai Medical Center
Los Angeles, CA

Mark Pimentel, MD, is Professor of Medicine, Geffen School of Medicine and Associate Professor at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and internationally. A few of Dr. Pimentel’s most significant accomplishments include: 1. The discovery of rifaximin as a treatment for irritable bowel syndrome (IBS); 2. He developed the first blood test for IBS on the basis of IBS being derived from acute gastroenteritis; 3. Described the association between IBS and bacterial overgrowth which forms the basis for microbiome therapies in this condition; 4. Uncovered the methanogen (M. smithii) as an agent for causing constipation in humans; and 5. Discovered the use of lovastatin as a microbiome treatment for constipation on the basis of inhibiting methane production by methanogens.


Send Email for Mark Pimentel


Breakfast D: Case-Based Functional GI Testing: Ask the Experts

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Breakfast D: Case-Based Functional GI Testing: Ask the Experts